Retaklik Retatrutide 30mg UAE – Research & Product Information

Description

Retaklik Retatrutide 30mg UAE is a product listing associated with retatrutide, an investigational compound being studied in clinical research. Retatrutide is also known by the development code LY3437943 and is being investigated as a triple receptor agonist involving the GIP, GLP-1 and glucagon pathways.

Retatrutide has received significant scientific attention because researchers are studying whether simultaneous activity across these three pathways can influence body weight, glucose-related outcomes and other metabolic measures. ClinicalTrials.gov continues to list active retatrutide development programs, including Phase 3 and Phase 3b studies.

The Pureness X page currently lists the product as Retatrutide 30mg UAE with a displayed price of AED 800. This is a store listing price and should not be interpreted as an official UAE medicine price.

Most importantly, retatrutide should not be confused with an approved prescription medicine. UAE health authorities have warned about unauthorized retatrutide products, while retatrutide remains under clinical development.

Quick Product Overview

Product Information

Details

Listed product name

Retaklik Retatrutide 30mg

Listed strength

30 mg

Active research compound

Retatrutide

Development code

LY3437943

Research mechanism

GIP + GLP-1 + glucagon

Research classification

Investigational

Listed UAE price

AED 800

Primary topic

Clinical and scientific research

The product name, stated strength and displayed price above reflect the current Pureness X listing.

What Is Retatrutide?

Retatrutide, also known as LY3437943, is an investigational molecule being developed by Eli Lilly.

Its main scientific feature is its activity across three receptor pathways:

• GLP-1 receptor
• GIP receptor
• Glucagon receptor

Because of this combination, retatrutide is commonly described in scientific literature as a triple agonist.

This distinguishes it from medicines or investigational compounds that target only one receptor pathway.

Researchers are studying the combined effects of these pathways because they are involved in appetite regulation, glucose metabolism and energy balance.

What Does the Triple-Agonist Mechanism Mean?

The term triple agonist refers to activity at three hormone receptor systems.

GLP-1 Pathway

GLP-1 signalling is involved in appetite regulation, satiety and glucose-related processes.

GIP Pathway

GIP is involved in glucose-dependent insulin signalling and broader metabolic processes.

Glucagon Pathway

Glucagon is involved in energy metabolism and regulation of stored energy.

Retatrutide is being investigated because researchers want to understand whether activating these pathways together can produce clinically meaningful metabolic effects.

The mechanism itself does not establish that retatrutide is approved or appropriate for individual treatment.

Retatrutide and Clinical Research

Retatrutide has progressed considerably through clinical development.

ClinicalTrials.gov currently lists studies evaluating retatrutide in people with obesity or overweight and other research populations. For example, TRIUMPH-6 is a Phase 3b study investigating maintenance of weight reduction, while TRIUMPH-8 is a Phase 3b study evaluating efficacy and safety in people with obesity or overweight.

Another Phase 3b study, TRIUMPH-9, is investigating different dose-escalation approaches in participants without type 2 diabetes who have obesity or overweight.

These studies demonstrate ongoing scientific development, but clinical development should not be confused with regulatory approval.

Retatrutide and Weight-Management Research

Weight management is one of the major research areas involving retatrutide.

Published clinical research has investigated changes in body weight, body composition and metabolic outcomes. Research findings can provide information about the potential of an investigational compound, but results from clinical trials cannot guarantee the same outcome for an individual.

The appropriate interpretation of clinical-trial results depends on:

• Study population
• Dose and treatment schedule
• Study duration
• Trial design
• Safety findings
• Statistical analysis
• Regulatory review

For this reason, online product descriptions should not turn clinical-trial findings into promises about individual weight loss.

Retatrutide vs GLP-1 Research

Retatrutide is sometimes described as a next-generation metabolic compound because it acts on three receptor pathways rather than one.

Research approach

Main receptor pathways

GLP-1 agonist

GLP-1

GLP-1/GIP dual agonist

GLP-1 + GIP

Retatrutide

GLP-1 + GIP + glucagon

This difference in receptor activity is one of the main scientific reasons retatrutide is being investigated.

However, mechanism alone should not be used to claim that retatrutide is automatically better than approved medicines.

What Is LY3437943?

LY3437943 is the development code associated with retatrutide.

When researching retatrutide online, using both terms can be useful because scientific papers and clinical-trial records may use LY3437943 instead of the name retatrutide.

For research purposes, useful search terms include:

• Retatrutide
• LY3437943
• Retatrutide clinical trial
• Retatrutide Phase 3
• Retatrutide triple agonist

ClinicalTrials.gov uses both retatrutide and LY3437943 in its trial information.

Retaklik Retatrutide 30mg Product Information

The current Pureness X listing identifies the product as Retatrutide 30mg UAE and displays a price of AED 800.

For any research-product listing, users should independently verify relevant documentation rather than relying solely on a product-page description.

Important information to verify may include:

Product identity

Confirm the stated compound name and strength.

Batch information

Check whether a specific batch or lot number is provided.

Laboratory documentation

Where available, review batch-specific laboratory documentation.

Certificate of Analysis

A COA should be evaluated for the actual batch rather than treated as proof that every product from a supplier has the same characteristics.

Supplier information

Verify the identity and provenance of the supplier.

Regulatory status

Check the current requirements of the relevant UAE health authority.

Retatrutide UAE Regulatory Status

This is one of the most important sections for this page.

The UAE Department of Health issued a March 2026 alert warning the public and healthcare/pharmaceutical sector about unauthorized retatrutide products. The alert states that retatrutide remains under clinical development and that there is no authorized supply or legitimate distribution in global markets.

Therefore, an online listing should not be presented as evidence that retatrutide is an approved UAE medicine.

Important distinction

Online listing ≠ regulatory approval

Clinical trial ≠ public authorization

Product price ≠ official UAE medicine price

Product claim ≠ laboratory verification

This distinction is particularly important for anyone searching for Retatrutide 30mg UAE or related terms.

Is Retatrutide Approved in the UAE?

Current UAE health-authority information indicates that retatrutide is not an authorized medicine for routine public use. The Department of Health has specifically warned against unauthorized retatrutide products.

Therefore, this page should not describe retatrutide as an approved UAE medication or claim that it is routinely available through UAE pharmacies.

Retatrutide Safety Research

Safety is an essential part of the ongoing clinical-development process.

Clinical trials are designed to investigate both potential benefits and adverse events in controlled populations.

Researchers evaluate factors such as:

• Gastrointestinal adverse events
• Changes in metabolic parameters
• Cardiovascular measurements
• Tolerability
• Treatment discontinuation
• Longer-term safety

Because retatrutide remains investigational, its complete safety profile continues to be evaluated through clinical research.

For that reason, this product page should not provide personalized dosing or injection instructions.

Why Clinical Trials Matter

Clinical trials help researchers answer questions that cannot be answered through product descriptions alone.

They evaluate:

1. Efficacy — whether a compound produces meaningful effects.
2. Safety — what adverse events occur.
3. Dose response — how outcomes vary across research doses.
4. Population differences — how different groups respond.
5. Longer-term outcomes — what happens with extended exposure.
6. Regulatory evidence — whether the total evidence supports potential approval.

ClinicalTrials.gov continues to list retatrutide studies across different phases and research populations.

What Should Researchers Check Before Relying on a Product Listing?

Anyone researching an online peptide or investigational-compound listing should consider several verification points.

1. Compound identity

Check whether the claimed compound is clearly identified.

2. Batch information

Look for a specific lot or batch number.

3. Testing documentation

Review available laboratory documentation and understand exactly what was tested.

4. Certificate of Analysis

Check whether the documentation relates to the actual batch.

5. Storage information

Verify storage requirements against reliable product documentation.

6. Regulatory status

Confirm whether the compound is authorized for the intended use in the relevant jurisdiction.

7. Intended use

Do not assume that a research listing is equivalent to an approved medicine.

Retatrutide 30mg UAE Price Information

The Pureness X page currently displays AED 800 for the listed product.

However, this should be described as an online product listing price, not an official UAE medicine price.

Because retatrutide is not authorized for routine public use in the UAE, online prices should not be interpreted as regulated pharmacy pricing. The UAE Department of Health's warning is particularly relevant when evaluating online retatrutide claims.

Frequently Asked Questions

What is Retaklik Retatrutide 30mg?

The Pureness X page lists Retaklik Retatrutide 30mg as a 30 mg retatrutide product. Retatrutide itself is an investigational compound being studied in clinical research.

What is retatrutide?

Retatrutide is an investigational compound also known as LY3437943. It is being studied as a triple receptor agonist involving GLP-1, GIP and glucagon pathways.

What is LY3437943?

LY3437943 is the development code associated with retatrutide and is used in clinical-trial and scientific research records.

Is retatrutide approved in the UAE?

No. UAE health authorities have warned about unauthorized retatrutide products and state that the compound remains under clinical development.

What is the listed price of Retaklik Retatrutide 30mg?

The Pureness X page currently displays AED 800. This is an online listing price, not an official regulated UAE medicine price.

Is retatrutide a GLP-1-only compound?

No. Retatrutide is being investigated as a triple agonist involving GLP-1, GIP and glucagon receptors.

What is Retatrutide Phase 3?

Phase 3 refers to later-stage clinical research designed to evaluate efficacy and safety in larger populations. Retatrutide has ongoing Phase 3/3b clinical development programs.

Final Thoughts

Retatrutide has become an important subject in metabolic-health research because of its triple-receptor mechanism involving GLP-1, GIP and glucagon.

For people researching Retaklik Retatrutide 30mg UAE, the most important issue is to distinguish between an online product listing and an approved medicine.

Retatrutide remains an investigational compound, and UAE authorities have issued a warning regarding unauthorized retatrutide products.

Scientific and clinical-trial information can help readers understand the compound, but it should not be interpreted as a recommendation for individual treatment or as proof that an online product is authentic, safe or legally authorized.

Medical & Regulatory Disclaimer

This content is provided for educational and research-information purposes only. Retatrutide remains investigational and should not be represented as an approved UAE medicine.

This page does not provide individualized medical advice, dosing instructions, injection instructions or treatment recommendations.

Online product availability or pricing does not establish regulatory approval, authenticity, purity, safety or suitability for human use.

Readers should verify current UAE regulatory requirements and consult a qualified healthcare professional for medical questions.